BioMatrix Specialty Pharmacy (BioMatrix) recently announced that it is enhancing and expanding the company’s specialty infusion services and enhanced manufacturer program services, including product commercialization and HUB services.
As part of this strategy, effective February 17, 2023, BioMatrix divested certain pharmacy assets to CVS Specialty and will no longer distribute traditional specialty oral and self-injectable medications. BioMatrix will concentrate on servicing patients with bleeding disorders, receiving immune globulin (Ig) therapies and other specialty infusion medications in addition to providing high-touch patient access services and programs for our manufacturer partners.
BioMatrix offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. The company offers a tailored approach for a wide range of therapeutic categories, improving health and empowering patients to experience a higher quality of life.
In 2023, the M&A market for healthcare companies continues to build on STRATEGIC opportunities in the current market. The strategic corporate buyers and private equity investors remain committed to acquiring strong businesses that are well prepared for a transaction. Across the continuum of care, these buyers and investors are looking for well established, profitable businesses and offering prime valuations and options for management.
Do you know the current market value of your business? We do! We are here to help you plan, prepare, explore and succeed in executing your strategic options.
Contact Paragon Ventures for more information.
800-719-1555
